Results 251 to 260 of about 1,116,836 (319)

Effects of citric acid and heat-treated soybean meal on rumen fermentation characteristics, methane emissions, and microbiota: an <i>in vitro</i> study. [PDF]

J Anim Sci Technol
Yoo D, Oh J, Jeong S, Seo J.
europepmc   +1 more source

The Comparative Value of Urea and Linseed Meal for Milk Production

, 1943
I.W. Rupel, G. Bohstedt, E.B. Hart
openalex   +1 more source

THE SECRETION OF GASTRIC MUCIN IN MAN. A COMPARATIVE STUDY IN THE NORMAL SUBJECT AND IN THE PATIENT WITH PEPTIC ULCER IN RESPONSE TO AN ALCOHOL TEST MEAL [PDF]

, 1936
Richmond K. Anderson, Samuel J. Fogelson
openalex   +1 more source

Clinical Evaluation of Potential Interaction Between Bemnifosbuvir and Ruzasvir With an Assessment of Food Effect: Results of a Phase 1 Study in Healthy Participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract A combination of nucleotide hepatitis C virus (HCV) nonstructural protein (NS) 5B and 5A inhibitors is a preferred standard of care for treating chronic HCV. Bemnifosbuvir is a novel oral guanosine nucleotide prodrug with potent pan‐genotypic inhibitory activity against HCV NS5B.
Xiao‐Jian Zhou, Gaetano Morelli, Maureen Montrond, Shannan Lynch, Keith Pietropaolo, Bruce Belanger, Arantxa Horga, Janet Hammond   +7 more
wiley   +1 more source

Contamination of aflatoxin B₁, deoxynivalenol and zearalenone in feeds in China from 2021 to 2024. [PDF]

J Anim Sci Biotechnol
Liu M, Xia Z, Zhang Y, Yang R, Luo W, Guo L, Liu Y, Lamesgen D, Sun H, He J, Sun L.   +10 more
europepmc   +1 more source

Effect of Cytochrome P450 3A Inhibition and Induction by Itraconazole and Rifampin on Tazemetostat Pharmacokinetics in Patients With Advanced Malignancies

Clinical Pharmacology in Drug Development, EarlyView.
Abstract This study (NCT04537715) investigated itraconazole (strong cytochrome P450 [CYP] 3A inhibitor) and rifampin (strong CYP3A inducer) on tazemetostat pharmacokinetics. In Part 1, patients received tazemetostat 400 mg orally on Days 1, 15, and 36, and 400 mg twice daily on Days 3‐14 and Days 21‐35.
Yingxue Chen, Renli Teng, Attila Szanto, Apoorva Kapopara, Rajat Bannerji, Julien Ogier, Devalingam Mahalingam   +6 more
wiley   +1 more source

The Use of Soybean Meal in the Diet of Growing Chicks

, 1944
John C. Hammond, Harry W. Titus
openalex   +1 more source

Effect of Mild to Moderate Hepatic Impairment on Valemetostat Pharmacokinetics: An Open‐Label, Phase I Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Valemetostat tosylate (valemetostat) is a dual inhibitor of enhancer of zeste homolog (EZH) 2 and EZH1, approved in Japan for the treatment of relapsed/refractory peripheral T‐cell lymphoma and adult T‐cell leukemia/lymphoma. This Phase I, open‐label study evaluated the pharmacokinetics and safety of a single 50‐mg oral dose of valemetostat in
Masaya Tachibana, Thuy Vu Craveiro, Thomas C. Marbury, Samuel Oberstein, George J. Atiee, Ben Tao, Takako Shimizu, Yvonne Lau, Malaz A. Abutarif   +8 more
wiley   +1 more source

Daytime eating during simulated night work mitigates changes in cardiovascular risk factors: secondary analyses of a randomized controlled trial. [PDF]

Nat Commun
Chellappa SL, Gao L, Qian J, Vujovic N, Li P, Hu K, Scheer FAJL.   +6 more
europepmc   +1 more source

A 2‐Part, Open‐Label, Phase 1 Bioequivalence and Food‐Effect Study of Ubrogepant in Healthy Adult Participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract This Phase 1 study of ubrogepant was conducted to establish the bioequivalence (BE) of the 50‐ and 100‐mg to‐be‐marketed (TBM) tablet formulations with the clinical trial (CT) 100‐mg tablet formulation and evaluate the food effect on the bioavailability of the 100‐mg TBM tablet. This 2‐part study enrolled healthy participants aged 18‐45 years.
Ramesh Boinpally, Joel M. Trugman
wiley   +1 more source